Erratum: Placebo response in antipsychotic clinical trials: A meta-analysis (JAMA Psychiatry (2014) 71, 12 (1409-1421) DOI: 10.1001/jamapsychiatry.2014.1319);Placebo Response in antipsychotic clinical trials ameta-analysis

JAMA Psychiatry

Volumn 71, Issue 12, 2014, Pages 1409-1421

  Rutherford, Bret R ^a   Pott, Emily ^a   Tandler, Jane M ^a   Wall, Melanie M ^a   Roose, Steven P ^a   Lieberman, Jeffrey A ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO;

ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; HUMAN; META ANALYSIS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STUDY DESIGN; TREATMENT DURATION; ADULT; FEMALE; MALE; PSYCHOTIC DISORDERS; STATISTICAL MODEL; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LINEAR MODELS; MALE; PLACEBO EFFECT; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84915775143     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.2720     Document Type: Erratum

References (124)

1. Kinon BJ, Potts AJ,Watson SB. Placebo response in clinical trials with schizophrenia patients. Curr Opin Psychiatry. 2011;24(2):107-113
2. Walsh BT, Seidman SN, Sysko R, GouldM. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287 (14):1840-1847
3. Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010;36(3):504-509
4. Agid O, Siu CO, Potkin SG, et al.Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry. 2013;170(11):1335-1344
5. Mallinckrodt CH, Zhang L, PruckaWR, Millen BA. Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull. 2010;43(1):53-72
6. Alphs L, Benedetti F, FleischhackerWW, Kane JM. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol. 2012;15(7):1003-1014
7. Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013;170(7):723-733
8. Meltzer HY, Park S, Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Natl Acad Sci U S A. 1999;96(24):13591-13593
9. Dickerson FB. Cognitive behavioral psychotherapy for schizophrenia: a review of recent empirical studies. Schizophr Res. 2000;43(2-3):71-90
10. Bryk AS, Raudenbush SW. Hierarchical Linear Models. Newbury Park, CA: Sage Publications; 1992
11. HoxJ. Multilevel Analysis: Techniques and Applications. Mahwah, NJ: Lawrence Erlbaum Publishers; 2002
12. Haddock CK, Rindskopf D, Shadish WR. Using odds ratios as effect sizes formeta-analysis of dichotomous data: a primer on methods and issues. Psychol Methods. 1998;3(3):339-353. doi:10.1037/1082-989X.3.3.339.
13. Rutherford BR, Sneed JR, Roose SP. Does study design influence outcome? the effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom. 2009;78(3):172-181
14. Rutherford BR, Sneed JR, Tandler JM, Rindskopf D, Peterson BS, Roose SP. Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact. J AmAcad Child Adolesc Psychiatry. 2011;50(8):782-795
15. Rutherford BR, Tandler J, Brown P, Sneed JR, Roose SP. Clinic visits in late-life depression trials: effects on signal detection and therapeutic outcome [published online November 14, 2013]. Am J Geriatr Psychiatry. doi:10.1016/j.jagp.2013.09 .003
16. Higgins JPT, Thompson SG. Quantifying heterogeneity in ameta-analysis. Stat Med. 2002; 21(11):1539-1558
17. Takkouche B, Cadarso-Surez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologicmeta-analysis. Am J Epidemiol. 1999; 150(2):206-215
18. Addington DEN, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004;65(12): 1624-1633
19. Andersen K, d'Elia G, Hllberg B, Perris C, Rapp W, Romn G. A controlled trial of pimozide and trifluoperazine in chronic schizophrenic syndromes. Acta Psychiatr Scand Suppl. 1974;249:43-64
20. Arvanitis LA,Miller BG; Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997;42(4):233-246
21. Astrup C, Grimgrd A, Hebnes K, Kruse-Jensen A, LidM. A study of flupenthixol decanoate and pipotiazine undecylenate in schizophrenics. Acta Psychiatr Scand. 1974;50(5):481-491
22. Atmaca M, KulogluM, Tezcan E, Canatan H, Gecici O. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res. 2002;33(6):562-565
23. Bankier RG, Mathewson FAL. A clinical study of mesoridazine and chlorpromazine in relapsed schizophrenic patients. Dis Nerv Syst. 1972;33(8): 529-534
24. Bankier RG. A comparison of fluspirilene and trifluoperazine in the treatment of acute schizophrenic psychosis. J Clin Pharmacol NewDrugs. 1973;13(1):44-47
25. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7(2):125-137
26. Beasley CM Jr, Sanger T, SatterleeW, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996;124(1-2):159-167
27. Beasley CM Jr, Tollefson G, Tran P, SatterleeW, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14(2):111-123
28. Bechelli LPC, Ruffino-Netto A, Hetem G. A double-blind controlled trial of pipotiazine, haloperidol and placebo in recently-hospitalized acute schizophrenic patients. Braz J Med Biol Res. 1983;16(4):305-311
29. Bender S, Dittmann-Balcar A, Schall U, et al. Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol. 2006;9(2):135-145
30. Bressler B, Friedel RO. A comparison between chlorpromazine and thiothixene in a Veterans Administration Hospital population. Psychosomatics. 1971;12(4):275-277
31. Brook S,Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl). 2005;178(4):514-523
32. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32(1):36-45
33. Ceskov E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993;26(4):121-124
34. Chaudhry IB, Husain N, Khan S, Badshah S, Deakin B, Kapur S. Amoxapine as an antipsychotic: comparative study versus haloperidol. J Clin Psychopharmacol. 2007;27(6):575-581
35. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13(1):25-40
36. Chouinard G, Annable L. Pimozide in the treatment of newly admitted schizophrenic patients. Psychopharmacology (Berl). 1982;76(1):13-19
37. Clark ML, Huber WK, Kyriakopoulos AA, Ray TS, Colmore JP, Ramsey HR. Evaluation of trifluperidol in chronic schizophrenia. Psychopharmacologia. 1968;12(3):193-203
38. Clark ML, Ramsey HR, Ragland RE, Rahhal DK, Serafetinides EA, Costiloe JP. Chlorpromazine in chronic schizophrenia: behavioral dose-response relationships. Psychopharmacologia. 1970;18(3): 260-270
39. Clark ML, Huber WK, Sakata K, Fowles DC, Serafetinides EA. Molindone in chronic schizophrenia. Clin Pharmacol Ther. 1970;11(5):680-688
40. Clark ML, Huber WK, Sullivan J,Wood F, Costiloe JP. Evaluation of loxapine succinate in chronic schizophrenia. Dis Nerv Syst. 1972;33(12): 783-791
41. Clark ML, Paredes A, Costiloe JP,Wood F, Barrett A. Loxapine in newly admitted chronic schizophrenic patients. J Clin Pharmacol. 1975;15(4, pt 1):286-294
42. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992;85(4):295-305
43. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158(5):765-774
44. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med. 2000;30(1):95-105
45. Cutler AJ, Marcus RN, Hardy SA, O'Donnell A, Carson WH, McQuade RD. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr. 2006;11(9):691-702, quiz 719
46. Cutler AJ, Tran-Johnson T, Kalali A, AstrmM, Brecher M, Meulien D. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. Psychopharmacol Bull. 2010;43(4):37-69
47. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M; Ziprasidone Study Group. Ziprasidone 80mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology. 1999;20(5):491-505
48. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93(1-3):117-130
49. Dehnel LL, Vestre ND, Schiele BC. A controlled comparison of clopenthixol and perphenazine in a chronic schizophrenic population. Curr Ther Res Clin Exp. 1968;10(4):169-176
50. Dube KC, Kumar N. Loxapine succinate: a comparative study with chlorpromazine. Curr Ther Res Clin Exp. 1976;19(6):653-660
51. Edwards JG, Alexander JR, Alexander MS, Gordon A, Zutchi T. Controlled trial of sulpiride in chronic schizophrenic patients. Br J Psychiatry. 1980;137:522-529
52. Emsley RA; RisperidoneWorking Group. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull. 1999;25(4):721-729
53. Vianna Filho U, Versiani Caldeira V, Romildo Bueno J. The efficacy and safety of loxapine succinate in the treatment of schizophrenia: a comparative study with thiothixene. Curr Ther Res Clin Exp. 1975;18(3):476-490
54. Frangos H, Zissis NP, Leontopoulos I, et al. Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatr Scand. 1978;57(5): 436-446
55. Freeman H, Frederick AND. Comparison of trifluoperazine and molindone in chronic schizophrenic patients. Curr Ther Res Clin Exp. 1969;11(11):670-676
56. Freeman H. A double-blind comparison of mesoridazine and chlorpromazine in chronic schizophrenics. Dis Nerv Syst. 1973;34(6):289-293
57. Gelenberg AJ, Doller JC. Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. J Clin Psychiatry. 1979;40(5):238-240
58. Ghaleiha A, Honarbakhsh N, Boroumand MA, et al. Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. Hum Psychopharmacol. 2011;26(2):120-124
59. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247-256
60. Granacher RP, Ruth DD. A comparison of thioridazine (mellaril) and thiothixene (navane) in the treatment of hospitalized psychotic patients. Curr Ther Res. 1982;31(5):692-705. http://psycnet .apa.org/psycinfo/1982-33198-001. Accessed September 11, 2014
61. Grootens KP, van Veelen NMJ, Peuskens J, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull. 2011;37(2):352-361
62. Haas S, Beckmann H. Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. Pharmacopsychiatria. 1982;15 (2):70-74
63. Hrnryd C, Bjerkenstedt L, Bjrk K, et al. Clinical evaluation of sulpiride in schizophrenic patients-a double-blind comparison with chlorpromazine. Acta Psychiatr Scand Suppl. 1984; 311:7-30
64. Heikkil L, Laitinen J, Vartiainen H. Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients-a double-blind clinical multicentre investigation. Acta Psychiatr Scand Suppl. 1981;294:30-38
65. Hyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993;88(6):395-402
66. Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin Neurosci. 2001;55(4):403-414
67. Itil TM, Polvan N, Ucok A, Eper E, Gven F, Hsu W. Comparison of the clinical and electroencephalographical effects of molindone and trifluoperazine in acute schizophrenic patients. Behav Neuropsychiatry. 1971;3(9):6-13
68. Kahn RS, Schulz SC, Palazov VD, et al; Study 132 Investigators. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007; 68(6):832-842
69. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125-1132
70. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1-3):147-161
71. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63 (9):763-771
72. Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2009;70(4):572-581
73. Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl). 1998;140(2):173-184
74. Kiloh LG, Williams SE, Grant DA, Whetton PS. A double-blind comparative trial of loxapine and trifluoperazine in acute and chronic schizophrenic patients. J Int Med Res. 1976;4(6):441-448
75. Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28(4):392-400
76. Klieser E, Lehmann E, Kinzler E,Wurthmann C, Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol. 1995;15(1)(suppl 1):45S-51S
77. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia: results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635-647
78. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790-799
79. Lin CH, Kuo CC, Chou LS, et al. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J Clin Psychopharmacol. 2010;30(5):518-525
80. LuckeyWT, Schiele BC. A comparison of haloperidol and trifluoperazine (a double-blind, controlled study on chronic schizophrenic outpatients). Dis Nerv Syst. 1967;28(3):181-186
81. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebocontrolled study. Biol Psychiatry. 2007;62(12):1363-1370
82. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151(6):825-835
83. Martin S, Ljo H, Peuskens J, et al; SOLIANOL Study Group. A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Curr Med Res Opin. 2002;18 (6):355-362
84. McIndoo MV. A controlled study of mesoridazine: an effective treatment for schizophrenia. South Med J. 1971;64(5):592-596
85. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study. Am J Psychiatry. 2011; 168(9):957-967
86. Mller HJ, Riedel M, Jger M, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol. 2008;11(7):985-997
87. Moore DF. Treatment of acute schizophrenia with loxapine succinate (Loxitane) in a controlled study with chlorpromazine. Curr Ther Res Clin Exp. 1975;18(1, pt 2):172-180
88. Moyano CZ. A double-blind comparison of loxitane-loxapine succinate and trifluoperazine hydrochloride in chronic schizophrenic patients. Dis Nerv Syst. 1975;36(6):301-304
89. NakamuraM, OgasaM, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829-836
90. PalestineML. Comparative study of two antipsychotic drugs in a state hospital.Dis Nerv Syst. 1972;33(6):395-402
91. Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):218-226
92. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3): 235-244
93. Pecknold JC, McClure DJ, Allan T,Wrzesinski L. Comparison of pimozide and chlorpromazine in acute schizophrenia. Can J Psychiatry. 1982;27(3): 208-212
94. Peuskens J; Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166(6):712-726, discussion 727-733
95. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96(4): 265-273
96. Potkin SG, Saha AR, KujawaMJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60(7):681-690
97. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492-1500
98. Potkin SG, Litman RE, Torres R,Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2)(suppl 1):S4-S11
99. Rickels K, Byrdy H, Valentine J, PostelW, Norstad N, Downing R. Double-blind trial of thiothixene and chlorpromazine in acute schizophrenia. Int Pharmacopsychiatry. 1978;13(1): 50-57
100. Riedel M, Mller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005; 255(6):432-437
101. Ritter RM, Tatum PA. Two studies of the effects ofmesoridazine. J Clin Pharmacol NewDrugs. 1972;12(8):349-355
102. Russell N, Landmark J, Merskey H, Turpin T. A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia. Can J Psychiatry. 1982;27(7):593-596
103. Selman FB, McClure RF, Helwig H. Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics. Curr Ther Res Clin Exp. 1976;19(6):645-652
104. Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia: chemically unrelated antipsychotics as therapeutic alternatives. J Nerv Ment Dis. 1972;154(1):31-42
105. Shopsin B, Klein H, Aaronsom M, Collora M. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry. 1979;36(6):657-664
106. Silverstone T, Cookson J, Ball R, et al. The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. J Psychiatr Res. 1984; 18(3):255-268
107. Simpson GM, Angus JWS, Edwards JG. A controlled study of haloperidol in chronic schizophrenia. Curr Ther Res Clin Exp. 1967;9(8): 407-412
108. Simpson GM, AminM, Edwards JG. A double-blind comparison of molindone and trifluoperazine in the treatment of acute schizophrenia. J Clin Pharmacol New Drugs. 1971;11 (3):227-236
109. Simpson GM, Cuculic Z. A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients. J Clin Pharmacol. 1976;16(1):60-65
110. Sirota P, Pannet I, Koren A, Tchernichovsky E. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Hum Psychopharmacol. 2006;21(4):227-234
111. Small JG, Hirsch SR, Arvanitis LA,Miller BG, Link CG; Seroquel Study Group. Quetiapine in patients with schizophrenia: a high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry. 1997;54(6):549-557
112. Steinbook RM, Goldstein BJ, Brauzer B, Moreno SS, Jacobson AF. Loxapine: a double-blind comparison with chlorpromazine in acute schizophrenic patients. Curr Ther Res Clin Exp. 1973; 15(1):1-7
113. Sugerman AA,Williams BH. Trifluperidol and trifluoperazine in acute schizophrenic patients. J New Drugs. 1965;5(5):318-326
114. Tollefson GD, Beasley CMJr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154(4):457-465
115. Tuason VB, Escobar JI, GarveyM, Schiele B. Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study. J Clin Psychiatry. 1984;45(4):158-163
116. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159(2):255-262
117. Wolpert A, Sheppard C, Merlis S. Thiothixene, thioridazine, and placebo in male chronic schizophrenic patients. Clin Pharmacol Ther. 1968;9 (4):456-464
118. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry. 2006;67(7):1093-1103
119. Zimbroff D,Warrington L, Loebel A, Yang R, Siu C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol. 2007;22(6):363-370
120. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry. 2009; 166(1):42-49
121. Small GW, Schneider LS, Hamilton SH, et al. Site variability in a multisite geriatric depression trial. Int J Geriatr Psychiatry. 1996;11:1089-1095. doi:10.1002/(SICI)1099-1166(199612)11:123.0.CO;2-F
122. Leucht S, Heres S, Davis JM. Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle. Am J Psychiatry. 2013;170 (11):1232-1234
123. Kobak KA, Leuchter A, DeBrota D, et al. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacol. 2010;30(2):193-197
124. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980